Updates in Treatment and Management of Metastatic Castration-Resistant Prostate Cancer

Expert oncologists work together to review the current treatment paradigm for metastatic castration-resistant prostate cancer in the context of clinical trials and real-world experience.

EP. 1: Overview on Metastatic CRPC and Available Treatment Options

December 12th 2022

Expert oncologists Tanya Dorff, MD, and Elisabeth Heath, MD, FACP, reflect on the current treatment paradigm for patients with metastatic castration-resistant prostate cancer (mCRPC).

EP. 2: Practical Considerations for Sequencing Cabazitaxel in Metastatic CRPC

December 12th 2022

Centering discussion on the use of cabazitaxel in metastatic CRPC, key opinion leaders consider optimal sequencing of therapy in light of the TROPIC clinical trial.

EP. 3: The PROSELICA Trial: Cabazitaxel Dosing in Metastatic CRPC

December 19th 2022

Expert perspectives on the PROSELICA trial, which helped inform optimal dosing strategies with cabazitaxel in metastatic castration-resistant prostate cancer.

EP. 4: Interpreting Data From the CARD Trial in Metastatic CRPC

December 19th 2022

Tanya Dorff, MD, and Elisabeth Heath, MD, FACP, review data from the CARD trial and discuss the nuanced selection and sequencing of treatment in metastatic CRPC.

EP. 5: Metastatic CRPC: Considering Use of Combination Cabazitaxel/Carboplatin

December 26th 2022

Switching their focus to combination therapy in metastatic CRPC, expert oncologists review trial results from a study analyzing cabazitaxel/carboplatin therapy.

EP. 6: Optimizing Patient Selection for Cabazitaxel Therapy in Metastatic CRPC

December 26th 2022

A brief review of factors that may influence an academic or community physician’s choice to utilize cabazitaxel in the setting of metastatic castration-resistant prostate cancer.

EP. 7: Metastatic CRPC: Selecting Patients for Cabazitaxel or Radiotherapy

January 2nd 2023

Comprehensive insight on factors that may influence the selection of cabazitaxel or radiotherapy for patients with metastatic castration-resistant prostate cancer.

EP. 8: Addressing Barriers to Care in Metastatic Castration-Resistant Prostate Cancer

January 2nd 2023

Tanya Dorff, MD, and Elisabeth Heath, MD, FACP, share perspective on the challenges inherent in delivering novel therapy to patients diagnosed with metastatic CRPC.

EP. 9: Metastatic CRPC Management: Future Directions in Care

January 9th 2023

Closing out their review of the metastatic CRPC treatment paradigm, Tanya Dorff, MD, and Elisabeth Heath, MD, FACP, look toward future evolutions in care.